Fri, Mar 6, 2015, 9:45 AM EST - U.S. Markets close in 6 hrs 15 mins

Recent

% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

pharmainvestor1998 73 posts  |  Last Activity: 12 minutes ago Member since: Jun 23, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • pharmainvestor1998 pharmainvestor1998 12 minutes ago Flag

    The first line therapies are very effective and well tolerated, hence the CDC lists them as first-line therapy, and it is no surprise that they command the greatest market share.

    In contrast, intralesional interferons are considered an "alternative regimen" with "more side effects and/or less data on efficacy" by the CDC:

    "Alternative regimens include treatment options that might be associated with more side effects and/or less data on efficacy. Alternative regimens include intralesional interferon, photodynamic therapy, and topical cidofovir."

    Hence, it is also no surprise that interferons constitute a much smaller market share, and given Alferon's increased cost without evidence of benefit compared with Intron A, it is no surprise that Alferon's sales were microscopic.

    From the FDA's report of 2007:

    "Total Prescriptions Market Share
    TOTAL MARKET 1,623,092; 100.0%
    Aldara (imiquimod) 1,194,224; 73.6%
    Carac (flurouracil) 229,905; 14.2%
    Efudex (flurouracil)173,308; 10.7%
    Intron A (interferon alfa-2b) 12,710 ;0.8%
    Fluoroplex (flurouracil) 12,467; 0.8%
    Alferon N (interferon alfa-n3) 478; 0.0%"

    So, the for the most recent year in which Alferon was still being sold, intralesional interferons had only 0.8% of the market, with Alferon making up 0.0% (lol)

    And, with increasing use of HPV vaccines such as Gardasil, the market for genital warts therapies can be expected to shrink considerably in the coming years.

    So, for anyone who is not a paid pumper, it is glaringly obvious that the market for Alferon will remain very limited.

  • Alferon sold very poorly before HEB stopped sales in 2008. It is still not a preferred treatment option on the CDC's STD guidelines. And, the increasing use of Gardasil will lead to a decreased incidence of genital warts.

    From the CDC's STD guidelines:

    "Recommended Regimens for External Genital Warts

    Patient-Applied:
    Podofilox 0.5% solution or gel
    OR
    Imiquimod 5% cream
    OR
    Sinecatechins 15% ointment

    Provider–Administered:
    Cryotherapy with liquid nitrogen or cryoprobe. Repeat applications every 1–2 weeks.
    OR
    Podophyllin resin 10%–25% in a compound tincture of benzoin
    OR
    Trichloroacetic acid (TCA) or Bichloroacetic acid (BCA) 80%–90%
    OR
    Surgical removal either by tangential scissor excision, tangential shave excision, curettage, or electrosurgery."

    "Alternative regimens include treatment options that might be associated with more side effects and/or less data on efficacy. Alternative regimens include intralesional interferon, photodynamic therapy, and topical cidofovir."

    "A limited number of case reports of severe systemic effects resulting from treatment with podophyllin resin and interferon have been documented."

    "The Gardasil vaccine, which has been approved for use in males and females aged 9–26 years, protects against the HPV types that cause 90% of genital warts (i.e., types 6 and 11)."

  • pharmainvestor1998 pharmainvestor1998 8 hours ago Flag

    They put you back on the late shift at Applebee's, ewan? Sorry to hear that.

  • Reply to

    Alferon has been a commercial flop.

    by supersavvyinvestor Mar 2, 2015 10:48 AM
    pharmainvestor1998 pharmainvestor1998 Mar 3, 2015 1:04 AM Flag

    The 10K will be out in a few weeks, and it should give us an idea of how many shares HEB has dumped onto the market for its recent pumps.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 9:21 AM Flag

    It is with great regret that I must report that I have failed in teaching jonjon how to spot and avoid logical fallacies.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 9:15 AM Flag

    Using jonjon's flawed logic, I will say that I have yet to see a single link proving that jonjon is not a pederast.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 9:07 AM Flag

    Compared to Peterson, the IOM is the Voice of God.

    I don't know why dumbdumb is so flustered over this. It was just a sloppy mistake by the author of the pumping press release, that's all.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 8:59 AM Flag

    Dumbdumb, all of my quotes in this thread are from the IOM report, including: "Low NK cytotoxicity is not specific to ME/CFS. ...It is present as well in healthy individuals who are older, smokers, psychologically stressed, depressed, physically deconditioned, or sleep deprived "

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 8:45 AM Flag

    "Low NK cytotoxicity is not specific to ME/CFS. ...It is present as well in healthy individuals who are older, smokers, psychologically stressed, depressed, physically deconditioned, or sleep deprived "

    A test that cannot distinguish between CFS, depression, physical deconditioning, sleep deprivation or psychological stress is worthless for diagnosing CFS or identifying subgroups.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 8:40 AM Flag

    It really makes you wonder whether or not anyone at HEB actually read the IOM report before slapping together that press release for the Monday morning pump.

    If the person writing the pumping press release had actually read the report, they would have edited out the paragraph mentioning NK-cells.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 8:38 AM Flag

    The IOM has come to different conclusions than Dr. Peterson.

    And, in the world of medicine, the IOM far outranks Dr. Peterson.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 8:36 AM Flag

    A test that cannot distinguish between CFS and the conditions of being "psychologically stressed, depressed, physically deconditioned, or sleep deprived" is simply not a useful test for CFS.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 8:34 AM Flag

    The pumpers on this board do no understand the concept of "specificity" in medical tests.

    "Low NK cytotoxicity is not specific to ME/CFS."

    At test that is positive for people "healthy individuals who are older, smokers, psychologically stressed, depressed, physically deconditioned, or sleep deprived" is not specific enough to be a useful test for CFS.

  • Reply to

    IOM and NK Cells

    by pharmainvestor1998 Feb 25, 2015 7:06 AM
    pharmainvestor1998 pharmainvestor1998 Feb 25, 2015 8:17 AM Flag

    "Low NK cytotoxicity is not specific to ME/CFS. It is also reported to be present in patients with rheumatoid arthritis, cancer, and endometriosis (Meeus et al., 2009; Oosterlynck et al., 1991; Richter et al., 2010). It is present as well in healthy individuals who are older, smokers, psychologically stressed, depressed, physically deconditioned, or sleep deprived "

  • pharmainvestor1998 by pharmainvestor1998 Feb 25, 2015 7:06 AM Flag

    It is interested that in HEB's recent press release on the IOM included HEB blather about NK cells. But, the IOM report notes that while NK-cells are an item of interest, the data so far is mixed.

    "On the other hand, one study with 26 ME/CFS patients and 50 controls failed to demonstrate impaired NK cell function in the ME/CFS patients using a K562 chromium (Cr) release assay of peripheral blood lymphocytes (PBLs) (Mawle et al., 1997). The authors of this study do not report NK cell counts or CD3-CD56+, but as described, NK numbers generally are not low in ME/CFS.

    Low NK cytotoxicity is not specific to ME/CFS. It is also reported to be present in patients with rheumatoid arthritis, cancer, and endometriosis (Meeus et al., 2009; Oosterlynck et al., 1991; Richter et al., 2010). It is present as well in healthy individuals who are older, smokers, psychologically stressed, depressed, physically deconditioned, or sleep deprived (Fondell et al., 2011; Whiteside and Friberg, 1998; Zeidel et al., 2002).

    A few studies found a correlation between the severity of NK cell functional impairment and the severity of disease in ME/CFS patients (Lutgendorf et al., 1995; Ojo-Amaize et al., 1994; Siegel et al., 2006). Others looked at mechanisms of cellular dysfunction in ME/CFS and identified abnormalities in early activation markers (Mihaylova et al., 2007) and perforin and granzyme concentration (Maher et al., 2005), as well as in the genes that regulate these cellular functions (Brenu et al., 2011, 2012a).
    However, no replication studies have been published.

    There also are studies enumerating the numbers of NK cells in ME/CFS patients, sometimes employing different identifying markers. NK cell count shows substantial heterogeneity in these patients, and there are no consistent findings (Barker et al., 1994; Brenu et al., 2010, 2011, 2012b; Caligiuri et al., 1987; Curriu et al., 2013; Fletcher et al., 2010; Gupta and Vayuvegula, 1991; Henderson, 2014; Klimas et al., 1990; Lev

  • Reply to

    The best news....

    by jonjonson1234 Dec 19, 2007 7:32 PM
    pharmainvestor1998 pharmainvestor1998 Feb 20, 2015 12:54 AM Flag

    I think that luckyman's assessment of HEB was true then, and remains true now.

    "luckyman18 • Dec 19, 2007 10:56 PM Flag

    LOL, dumbdumb the following is my honest fwiw. I seriously doubt that any reasonably successful company out there, and certainly no major pharma, would ever be interested in buying this company. I doubt ampligen will ever be approved for anything, highly unlikely ever for cfs. Alferon has very limited potential, I think the old ISI company sold more 5+ years ago than HEB does now. Oral interferons have never worked as far as I can tell. That leaves possible adjuvant uses, competing against other novel proprietary molecules for what is likely to take years of development and for small scraps of the vaccine pie. No dumbdumb, any merger if it ever happened IMHO would be with another doggie company, creating just a larger bowwow. The old story of one $70M market cap company merging with another of equal cap, then trying to convince shareholders and the market that the "synergies" are so huge that the newco is worth at least $500M the next day..."

  • pharmainvestor1998 pharmainvestor1998 Feb 19, 2015 8:30 PM Flag

    BTW, I had suspected that adamisamoron was another ewan id, thank you for confirming this one as well.

  • pharmainvestor1998 pharmainvestor1998 Feb 19, 2015 8:23 PM Flag

    ewan, I do not see any deleted posts in February. I just haven't posted much this month. I only post here for the lol's, and have been busy with other things.

    But, your concern is touching, ewan/oprah/bigtex4ya/almond_scent/sec_is_here/et al

  • pharmainvestor1998 pharmainvestor1998 Feb 19, 2015 12:33 PM Flag

    It was Cato that sued HEB. Cato lost and was told to pay $700k for legal expenses and court fees.

  • Reply to

    Luc and his 100+ fake ID's are on fire!!!!!

    by rogue_possum Feb 19, 2015 12:30 PM
    pharmainvestor1998 pharmainvestor1998 Feb 19, 2015 12:31 PM Flag

    The truckers haven't been tipping well lately, ewan?

BTX
4.30+0.01(+0.23%)9:43 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.